FindTrial
Sign In

Study of pharmacokinetics and the best way of administration of gefitinib for treated lung adenocarcinoma

Study of pharmacokinetics and the best way of administration of gefitinib for treated lung adenocarcinoma - Study of pharmacokinetics and the best way of administration of gefitinib for treated lung adenocarcinoma

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000000591
Enrollment
15
Registered
2007-02-15
Start date
2006-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung adenocarcinoma

Interventions

250mg of gefitinib, every other day. 250mg of gefitinib everyday, every other week.

Sponsors

International madical center of Japan
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Lung adenocarcinoma Treated case Performance status is less than 4 No interstitial pneumonitis Informed consent is given Enough function of major organs

Exclusion criteria

Exclusion criteria: severe complication pregnant diarrhea current smoker

Design outcomes

Primary

MeasureTime frame
Tolerance—

Secondary

MeasureTime frame
Pharmacokinetics of gefitinib Response rate—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026